mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice

详细信息    查看全文

• 作者：Philippe Barth¨¦l¨¦my ; Benjamin Hoch ; Christine Chevreau ; Florence Joly ; Brigitte Laguerre ; Fran?ois Lokiec ; Brigitte Duclos
• 关键词：Temsirolimus ; Everolimus ; Kidney cancer ; mTOR inhibitors
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：88
• 期：1
• 页码：42-56
• 全文大小：1264 K

文摘

To date, oral everolimus is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy, and intravenous temsirolimus for the first-line treatment of patients with poor prognosis metastatic renal cell carcinoma. However, some factors could guide the treatment choice aiming to individualize a treatment plan. Besides the crucial issue of treatment efficacy, other factors are to be considered such as disease status, histological subtype, extent of the disease, patient-specific factors, and agent-specific factors. All of these considerations have to stay in the frame of guideline recommendations which represent evidence-based medicine. The purpose of this article is to summarize the main pharmacological and pharmacokinetic characteristics of mTOR inhibitors, and to define targeted populations according to prognostic indexes.